Brought to you by 
Intrexon, Ziopharm license MD Anderson, U. Minnesota technologies for CART immunotherapies
05 Oct 2021
Executive Summary
Intrexon Corp. and Ziopharm Oncology Inc. licensed exclusive worldwide rights to the University of Texas’ MD Anderson Cancer Center’s technologies relating to chimeric antigen receptor T (CART) cells, which they will use with their own DNA platforms to develop and commercialize synthetic cellular immunotherapies for cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Immuno-Oncology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intrexon, Ziopharm license MD Anderson, U. Minnesota technologies for CART immunotherapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice